Economic considerations of macular edema therapies

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). Design A model of resource use, outcomes, and cost-effectiveness and utility. Participants None. Methods Results from published clinical trials (index studies) of laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) agents, and vitrectomy trials were used to ascertain visual benefit and clinical protocols. Calculations followed from the costs of 1 year of treatment for each treatment modality and the visual benefits as ascertained. Main Outcome Measures Visual acuity (VA) saved, cost of therapy, cost per line saved, cost per line-year saved, and costs per quality-adjusted life years (QALYs). Results The lines saved for DME (0.262.02), BRVO (0.744.92), and CRVO (1.23.75) yielded calculations of costs/line of saved VA for DME ($1329$11,609), BRVO ($494$13,039), and CRVO ($704$7611); costs/line-year for DME ($60$561), BRVO ($25$754), and CRVO ($45$473); and costs/QALY ($824 to $25,566). Conclusions Relative costs and benefits should be considered in perspective when applying and developing treatment strategies. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Original languageEnglish
Pages (from-to)1827-1833
Number of pages7
JournalOphthalmology
Volume118
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Retinal Vein Occlusion
Macular Edema
Economics
Retinal Vein
Costs and Cost Analysis
Cost-Benefit Analysis
Quality-Adjusted Life Years
Therapeutics
Visual Acuity
Vitrectomy
Disclosure
Clinical Protocols
Vascular Endothelial Growth Factor A
Adrenal Cortex Hormones
Lasers
Outcome Assessment (Health Care)
Clinical Trials

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Economic considerations of macular edema therapies. / Smiddy, William E.

In: Ophthalmology, Vol. 118, No. 9, 01.09.2011, p. 1827-1833.

Research output: Contribution to journalArticle

@article{0d372c5982514b3aa482dc3f71e45d60,
title = "Economic considerations of macular edema therapies",
abstract = "Purpose To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). Design A model of resource use, outcomes, and cost-effectiveness and utility. Participants None. Methods Results from published clinical trials (index studies) of laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) agents, and vitrectomy trials were used to ascertain visual benefit and clinical protocols. Calculations followed from the costs of 1 year of treatment for each treatment modality and the visual benefits as ascertained. Main Outcome Measures Visual acuity (VA) saved, cost of therapy, cost per line saved, cost per line-year saved, and costs per quality-adjusted life years (QALYs). Results The lines saved for DME (0.262.02), BRVO (0.744.92), and CRVO (1.23.75) yielded calculations of costs/line of saved VA for DME ($1329$11,609), BRVO ($494$13,039), and CRVO ($704$7611); costs/line-year for DME ($60$561), BRVO ($25$754), and CRVO ($45$473); and costs/QALY ($824 to $25,566). Conclusions Relative costs and benefits should be considered in perspective when applying and developing treatment strategies. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.",
author = "Smiddy, {William E}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.ophtha.2010.12.034",
language = "English",
volume = "118",
pages = "1827--1833",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Economic considerations of macular edema therapies

AU - Smiddy, William E

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Purpose To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). Design A model of resource use, outcomes, and cost-effectiveness and utility. Participants None. Methods Results from published clinical trials (index studies) of laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) agents, and vitrectomy trials were used to ascertain visual benefit and clinical protocols. Calculations followed from the costs of 1 year of treatment for each treatment modality and the visual benefits as ascertained. Main Outcome Measures Visual acuity (VA) saved, cost of therapy, cost per line saved, cost per line-year saved, and costs per quality-adjusted life years (QALYs). Results The lines saved for DME (0.262.02), BRVO (0.744.92), and CRVO (1.23.75) yielded calculations of costs/line of saved VA for DME ($1329$11,609), BRVO ($494$13,039), and CRVO ($704$7611); costs/line-year for DME ($60$561), BRVO ($25$754), and CRVO ($45$473); and costs/QALY ($824 to $25,566). Conclusions Relative costs and benefits should be considered in perspective when applying and developing treatment strategies. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.

AB - Purpose To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). Design A model of resource use, outcomes, and cost-effectiveness and utility. Participants None. Methods Results from published clinical trials (index studies) of laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) agents, and vitrectomy trials were used to ascertain visual benefit and clinical protocols. Calculations followed from the costs of 1 year of treatment for each treatment modality and the visual benefits as ascertained. Main Outcome Measures Visual acuity (VA) saved, cost of therapy, cost per line saved, cost per line-year saved, and costs per quality-adjusted life years (QALYs). Results The lines saved for DME (0.262.02), BRVO (0.744.92), and CRVO (1.23.75) yielded calculations of costs/line of saved VA for DME ($1329$11,609), BRVO ($494$13,039), and CRVO ($704$7611); costs/line-year for DME ($60$561), BRVO ($25$754), and CRVO ($45$473); and costs/QALY ($824 to $25,566). Conclusions Relative costs and benefits should be considered in perspective when applying and developing treatment strategies. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=80052445162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052445162&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2010.12.034

DO - 10.1016/j.ophtha.2010.12.034

M3 - Article

C2 - 21507488

AN - SCOPUS:80052445162

VL - 118

SP - 1827

EP - 1833

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 9

ER -